--- schema_version: "secwatch.filing_event.v1" accession: "0001493152-22-033864" form_type: "8-K" ticker: "PTIX" cik: "0001022899" company_name: "Protagenic Therapeutics, Inc.new" filed_at: "2022-11-29T23:59:59+00:00" generated_at: "2026-06-21T12:02:27.868746+00:00" event_type: "other_material" sentiment: "neutral" materiality_score: 0.55 calibrated_materiality_score: 0.55 confidence: "high" source: SEC EDGAR --- # Shareholders approve reverse split; company updates PT00114 trial timeline ## Summary - Stockholders approved a reverse stock split of 1:2 to 1:4, with board discretion on exact ratio. - Elected Khalil Barrage and Timothy R. Wright as Class I directors until 2025. - PT00114: U.S. IND submission expected by end of 2022; German ethics committee approved, awaiting BfArM. - Company anticipates Phase I start in Q1 2023 and first human safety readouts within 12 months. ## SEC filing metadata - accession: 0001493152-22-033864 - form_type: 8-K - ticker: PTIX - cik: 0001022899 - company_name: Protagenic Therapeutics, Inc.new - filed_at: 2022-11-29T23:59:59+00:00 - event_type: other_material - sentiment: neutral - materiality_score: 0.55 - calibrated_materiality_score: 0.55 - confidence: high - sec_items: 5.07, 8.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1022899/000149315222033864/0001493152-22-033864-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1022899/000149315222033864/form8-k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001493152-22-033864 - JSON: https://secwatch.observer/filing/0001493152-22-033864.json - Plain text: https://secwatch.observer/filing/0001493152-22-033864.txt ## Key facts - Shareholder Votes Protagenic Therapeutics, Inc.new shareholders approved Election of Class I directors to serve until the 2025 Annual Meeting. at the 2022-11-23 meeting. - Proposal: director election - Outcome: passed - Meeting: 2022-11-23 source text: Proposal One: The stockholders elected each of the following individuals as a Class I director to serve their terms until the Company’s 2025 Annual Meeting of Stockholders, and until their respective successors are duly elected and qualified. Name For Against Withheld Broker Non-Votes Khalil Barrage 5,949,384 - 469,906 3,815,159 Timothy R. Wright 6,372,127 - 47,163 3,815,159 evidence_url: https://www.sec.gov/Archives/edgar/data/1022899/000149315222033864/0001493152-22-033864-index.htm - Shareholder Votes Protagenic Therapeutics, Inc.new shareholders approved Ratification of the selection of MaloneBailey LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022. at the 2022-11-23 meeting. - Proposal: auditor ratification - Outcome: passed - Meeting: 2022-11-23 source text: Proposal Three: The stockholders ratified the selection of MaloneBailey LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022. For Against Abstain 9,963,481 260,269 10,699 evidence_url: https://www.sec.gov/Archives/edgar/data/1022899/000149315222033864/0001493152-22-033864-index.htm - Shareholder Votes Protagenic Therapeutics, Inc.new shareholders approved Approval of an amendment to the Third Amended and Restated Certificate of Incorporation to effect a reverse stock split in the range of 1-for-2 to 1-for-4, with the exact ratio to be set by the board. at the 2022-11-23 meeting. - Proposal: reverse split - Outcome: passed - Meeting: 2022-11-23 source text: Proposal Two: The stockholders approved an amendment to the Company’s Third Amended and Restated Certificate of Incorporation to effect a reverse stock split in the range of 1-for-2 to 1-for-4, with the exact ratio to be set within that range at the discretion of our board of directors without further approval or authorization of our stockholders and with our board of directors able to elect to abandon such proposed amendment and not effect the reverse split authorized by stockholders, in its sole discretion (the “ reverse split amendment ”). The Board only intends to implement the Reverse Stock Split to the extent it believes necessary to maintain our listing on NASDAQ for the future. For Against Abstain 9,224,529 978,121 31,799 evidence_url: https://www.sec.gov/Archives/edgar/data/1022899/000149315222033864/0001493152-22-033864-index.htm - Shareholder Votes Protagenic Therapeutics, Inc.new shareholders approved Advisory vote to approve named executive officer compensation. at the 2022-11-23 meeting. - Proposal: say on pay - Outcome: passed - Meeting: 2022-11-23 source text: Proposal Four: The stockholders approved an advisory vote to approve named executive officer compensation. As required by Section 14A of the Securities Exchange Act of 1934, we provided our stockholders with the opportunity to cast a non-binding advisory vote on the compensation of our named executive officers, as disclosed pursuant to Item 402 of Regulation S-K, including the compensation tables and narrative discussion beginning on page 11 of the proxy statement. The stockholders approved this proposal. For Against Abstain Broker Non-Votes 5,911,600 228,647 279,043 3,815,159 evidence_url: https://www.sec.gov/Archives/edgar/data/1022899/000149315222033864/0001493152-22-033864-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.